Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
1.990
-0.040 (-1.97%)
Jan 28, 2026, 8:02 AM EST - Market open
Invivyd Revenue
Invivyd had revenue of $13.13M in the quarter ending September 30, 2025, with 41.17% growth. This brings the company's revenue in the last twelve months to $50.04M, up 332.71% year-over-year. In the year 2024, Invivyd had annual revenue of $25.38M.
Revenue (ttm)
$50.04M
Revenue Growth
+332.71%
P/S Ratio
5.38
Revenue / Employee
$500,390
Employees
100
Market Cap
561.15M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.38M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Keros Therapeutics | 246.72M |
| CorMedix | 214.30M |
| Ginkgo Bioworks Holdings | 180.61M |
| LENZ Therapeutics | 17.50M |
| Lyell Immunopharma | 41.00K |
IVVD News
- 8 days ago - Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 - GlobeNewsWire
- 20 days ago - Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights - GlobeNewsWire
- 5 weeks ago - Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID - GlobeNewsWire
- 5 weeks ago - Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID - GlobeNewsWire
- 2 months ago - Invivyd to Participate at the 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 2 months ago - Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness - GlobeNewsWire
- 2 months ago - Invivyd: Maintaining Hold Rating With VYD2311 Alternative To Covid-19 Vaccination - Seeking Alpha
- 2 months ago - Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga